Alopecia areata after COVID-19 vaccination.

Alopecia areata COVID-19 Trichoscopy Vaccine

Journal

Clinical and experimental vaccine research
ISSN: 2287-3651
Titre abrégé: Clin Exp Vaccine Res
Pays: Korea (South)
ID NLM: 101592344

Informations de publication

Date de publication:
Jan 2022
Historique:
received: 07 09 2021
revised: 25 10 2021
accepted: 11 11 2021
entrez: 28 2 2022
pubmed: 1 3 2022
medline: 1 3 2022
Statut: ppublish

Résumé

The coronavirus disease 2019 (COVID-19) vaccines are authorized for use in numerous countries worldwide. Several cutaneous findings are reported after severe acute respiratory syndrome coronavirus 2 (SARS-COV-2) vaccination. Here, we report the case of a patient with a rapid onset of alopecia areata immediately after receiving the second dose of the COVID-19 vaccine. Alopecia areata is a common autoimmune disease leading to non-scarring hair loss. Among the many cutaneous adverse effects reported after the anti-SARS-COV2 vaccination, no episodes of alopecia areata have been described to date. In this paper, we report the first case of alopecia areata after COVID-19 vaccination described in the literature with a revision of cases of alopecia areata reported after other types of vaccination. Although the significance of these skin reactions is not yet known, further studies will certainly clarify whether the development of alopecia areata or other forms of immune-mediated reactions could represent a positive prognostic factor regarding immune protection from SARS-CoV-2.

Identifiants

pubmed: 35223675
doi: 10.7774/cevr.2022.11.1.129
pmc: PMC8844677
doi:

Types de publication

Case Reports

Langues

eng

Pagination

129-132

Informations de copyright

© Korean Vaccine Society.

Déclaration de conflit d'intérêts

No potential conflict of interest relevant to this article was reported.

Références

Dermatol Online J. 2021 Jan 15;27(1):
pubmed: 33560802
Eur Rev Med Pharmacol Sci. 2021 Feb;25(3):1663-1669
pubmed: 33629336
Int J Dermatol. 2021 Jul;60(7):891-892
pubmed: 33855706
Dermatol Ther. 2020 Nov;33(6):e14295
pubmed: 32909635
J Eur Acad Dermatol Venereol. 2021 Jul;35(7):e411-e412
pubmed: 33587766
JAMA. 1997 Oct 8;278(14):1176-8
pubmed: 9326478
Int J Dermatol. 2021 Jan;60(1):127
pubmed: 33226118
J Am Acad Dermatol. 2018 Jan;78(1):1-12
pubmed: 29241771
J Am Acad Dermatol. 2021 Jul;85(1):46-55
pubmed: 33838206
Med Clin (Barc). 2011 Mar 19;136(7):318
pubmed: 20451934
J Eur Acad Dermatol Venereol. 2021 Mar;35(3):e181-e183
pubmed: 33220124
Dermatol Ther. 2021 Mar;34(2):e14685
pubmed: 33331017
Br J Dermatol. 2022 Jan;186(1):142-152
pubmed: 34254291
Pediatr Dermatol. 2016 May;33(3):e218-9
pubmed: 27071855
J Cosmet Dermatol. 2021 Dec;20(12):3727-3729
pubmed: 34559937

Auteurs

Giuseppe Gallo (G)

Dermatology Unit, Department of Medical Sciences, University of Turin, Turin, Italy.

Luca Mastorino (L)

Dermatology Unit, Department of Medical Sciences, University of Turin, Turin, Italy.

Luca Tonella (L)

Dermatology Unit, Department of Medical Sciences, University of Turin, Turin, Italy.

Simone Ribero (S)

Dermatology Unit, Department of Medical Sciences, University of Turin, Turin, Italy.

Pietro Quaglino (P)

Dermatology Unit, Department of Medical Sciences, University of Turin, Turin, Italy.

Classifications MeSH